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The article by Freitas et al. in this issue of Endocrine Practice, “Study of the Prevalence of 
Autoimmune Thyroid Disease in Women with Breast Cancer”[1], adds a new piece to the intricate 
puzzle of what, if any, is the association between autoimmune thyroid disease and breast cancer. 
This controversial topic has been explored by many authors in the world’s literature during the past 
50 years. The findings have not been consistent but there appears to be a relationship between these 
two entities. 
 
In the 1950s a pioneering study by Sommers noted histological evidence of thyroid atrophy in 
patients with carcinoma of the breast, proposing an association between thyroid hypofunction and 
breast cancer [2]. Subsequent primary studies did not confirm that there was a relationship between 
Hashimoto thyroiditis and breast cancer as this impression was supported, by a meta-analysis of 13 
papers [3-14], that was published in 2002 [15]. In this meta-analysis Sarlis and coworkers applied 
broad criteria to the definition of Hashimoto thyroiditis, including patients with nodular goiter, the 
presence of antithyroid antibodies or simply reduced thyroid function [15]. More recent primary 
studies, however, supported a positive association. Eventually, in 2012, a new meta-analysis not 
only found a positive association between autoimmune thyroid disease and breast cancer, it also 
noted a positive association between goiter, anti-thyroid antibody and breast cancer [16]. The 
authors of this subsequent meta-analysis applied more specific inclusion criteria regarding the 
diagnosis of autoimmune thyroid disease, requiring the combination of two or more clinical 
parameters to confirm the diagnosis [16]. In addition they investigated the relationship between 
Graves’ disease and breast cancer as described in the literature, with only one study meeting the 
inclusion criteria [8]. This article by Giani and coworkers did not find a relationship between 
Graves’ disease and breast cancer [8]. Subsequently, in 2013, one Taiwanese study analyzed the 
risk of developing breast cancer in a population of 5025 patients with Graves’ disease, reporting an 
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adjusted Hazard Ratio (HR) of 1.58, based on a comparison with 20100 patients in the control 
group [17].  
Only few studies have analyzed the level of thyrotropin receptor antibody (TRAK), characteristic of 
Grave’s disease, as it relates to patients with breast cancer. In 2010 Ditsch and coworkers found 
higher concentrations of TRAK in patients with breast malignancy as compared to those with 
benign breast tumors and a healthy control group, however, the levels of TRAK never reached  
pathological values [18]. Recently, Prinzi and coworkers reported an increased prevalence of breast 
cancer in 139 patients with TRAK positivity as compared to the general population, however, after 
stratification by age, significant differences were noted only for those in the 45-59 age range [19].   
 
The most recent meta-analysis relating to anti-thyroid antibody titers and breast cancer, in 2014, 
concluded that thyroid peroxidase antibodies (TPOab) and thyroglobulin autoantibodies (TgAb) are 
higher in breast cancer patients than in women without breast cancer [20]. In addition, it was noted 
that FT3 and FT4 levels were significantly higher in breast cancer patients [20]. In the subgroup 
analyses, the authors noted area differences related to thyroid hormone levels but this observation 
was limited by lack of information regarding the mean age of patients in the articles analyzed; the 
authors noted this as a limitation of their study [20]. 
 
Studies have also tried to determine if there is a relationship between anti-thyroid antibody 
positivity/titers or thyroid hormones levels and the outcome of breast cancer patients. A 
retrospective analysis done by Smyth and coworkers found a better outcome in patients with breast 
cancer who had relatively high TPOab levels, using a cut-off of 0.3 U/mL [10]. Fiore and 
coworkers in 2007 replicated the study by Smyth and coworkers with a more accurate selection of 
patients in a prospective design; they found that the presence of anti-thyroid antibody, defined as 
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serum TgAb greater than 100 U/mL and/or TPOab values greater than 15 U/mL, was significantly 
related to a longer 5-year survival in breast cancer [21]. Other research groups noted a lower risk of 
metastasis in patients with breast cancer who had positive TPOab tests [22]. In apparent contrast, 
however, Cengiz and coworkers found that a subgroup of breast cancer patients with thyroid 
pathology, defined as any combination of a pathological result of thyroid function tests, high 
thyroid autoantibody levels or abnormal thyroid ultrasonography findings, had higher number of 
metastatic lymph nodes, bigger tumor volumes and more frequent vascular invasion [23]. 
Moreover, a prospective study of Jiskra et al. in 2007 did not find any difference in breast cancer 
survival in women with positive TgAb or TPOAb as compared to those with negative tests [24]. 
 
Serum thyroid hormone concentrations in breast cancer has not been extensively studied. Dulger 
and coworkers, in a 2004 report, did not find significant differences free triiodothyronine (FT3) or 
free thyroxine (FT4) in 16 patients with metastatic as compared to 34 patients with breast cancer but 
no metastases [25]. Fiore and coworkers in 2007 found median FT4 values of 8.6 pg/mL in the 
survivors group with breast cancer, not significantly different from 8.7 pg/mL in the group of 
patients with breast cancer who died [21]. The study by Jiskra and coworkers, also published in 
2007, did not find any prognostic relationship between serum levels of FT4 on relapse-free and 
overall survival in patients with breast cancer [24]. To summarize, there has not been a consistent 
relationship between antithyroid antibody positivity or titer and the outcome of breast cancer nor is 
this related to serum thyroid hormone concentrations.  
 
Selection biases may have contributed to the inconsistency of the literature in this field. Most 
studies recruited patients in third level oncologic centers with the possible occurrence of referral 
bias. In addition, the inclusion criteria for the studies have been heterogeneous as has been the tests 
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used to evaluate thyroid status. Some studies evaluated only thyroid hormone levels while others 
focused on markers of thyroid autoimmunity. In a few papers the thyroid was assessed with neck 
ultrasound and fine needle aspiration (FNA). Moreover, in some studies the patients were selected 
before the surgery to avoid the influence of the stress on the endocrine system, or after the surgery 
but before beginning of any adjuvant anti-tumoral therapy  to control the effect of chemotherapy on 
the immune response. Notably, however, most studies if not all studies have not been biased by 
studied subjects from regions that differed in iodine intake. 
 
In the majority of the studies the prevalence of benign thyroid disease has been assessed in a 
cohorts of patients with breast cancer, however few studies have looked at this issue from the 
opposite perspective, calculating the prevalence of breast cancer in a population with thyroid 
disease. In this regard Muller and coworkers in 2011 reported that the overall prevalence of breast 
cancer in patients with benign thyroid disease, defined with any type of thyroid antibody or with 
goiter, was significantly higher than that to be expected in the reference population [26].   
Recently, Prinzi et al. found an increased risk of breast cancer when a large cohort of 3921 patients 
with any thyroid disease were compared to the general population, but a lower risk when comparing 
patients with thyroid disease and positive autoantibodies to patients with thyroid disease and 
negative autoantibodies [19]. 
 
Some biases in this field are difficult to overcome. The high prevalence of both thyroid diseases and 
breast cancer in the fourth and fifth decade of women’s life may make it difficult to rule in or out an 
association between these entities. In this issue, the study by Freitas and coworkers, gives additional 
data in a well selected population and supports the hypothesis that there is little association between 
breast cancer and autoimmune thyroid disease [1]. This study defined autoimmune thyroid disease 
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patients as having any abnormality in a thyroid laboratory test (TSH, TPOab, TgAb) [1]. The 
patients included in the study group did not have any prior anti-tumor treatment and all the controls 
had a recent negative mammary ultrasound and/or mammography [1]. The only positive association 
found in the study was between a family history of thyroid disease and the presence of breast 
cancer, with the obvious limitation that the patient’s family history was self-reported by the patients 
rather than from potentially more reliable sources [1]. Other limitations of the study are the absence 
of neck ultrasound and FNA for more definitive characterization of the thyroid [1]. 
 
 
The effort to find a relationship between the pathogenesis of thyroid disease and breast cancer is not 
without a rationale. The Na/I Symporter (NIS), which imports I- from the blood-stream to the 
thyroid colloid and is also present in cancerous breast cells [27]. The presence of this and other 
shared antigens raises the question of whether autoimmunity against the thyroid gland may also 
affect breast cells but, as a recent study demonstrated, anti-NIS antibody staining in breast cancer 
tissue is weak [28]. It has also been reported that thyroid hormones mimic the effects of estrogen in 
breast cancer cells [29] but other studies have reported opposite findings [8].  
 
In conclusion, studies like that of Freitas et al. help to clarify the relationship, if any, between 
autoimmune thyroid disease and breast cancer. To date any such relationship seems more likely to 
be related to shared risk factors rather than to a direct influence of one entity on the other. Despite 
this impression more studies of a basic nature are indicated to determine if there are common 
factors that predispose to thyroid autoimmunity and breast cancer or if there are interactions that 
influence their courses. 
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